Stefano Crosignani

Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1<i>H</i>-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate

Stefano Crosignani, Patrick Bingham, Pauline Bottemanne et al. · Journal of Medicinal Chemistry · 2017 · 138 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

Discovery of a New Class of Potent, Selective, and Orally Bioavailable CRTH2 (DP2) Receptor Antagonists for the Treatment of Allergic Inflammatory Diseases

Stefano Crosignani, Patrick Page, Marc Missotten et al. · Journal of Medicinal Chemistry · 2008 · 103 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Bruno Gomes, Grégory Driessens, Derek W. Bartlett et al. · Molecular Cancer Therapeutics · 2018 · 85 citations · Full text

Medicine, Immunology, Oncology +17

Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors

Florence Schramme, Stefano Crosignani, Kim Frederix et al. · Cancer Immunology Research · 2019 · 69 citations · Full text

Medicine, Oncology, Pharmacology +17

Optimization of the Central Core of Indolinone–Acetic Acid-Based CRTH2 (DP2) Receptor Antagonists

Stefano Crosignani, Catherine Jorand‐Lebrun, Patrick Page et al. · ACS Medicinal Chemistry Letters · 2011 · 65 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14